[11C]Vinblastine - Syntheses and preliminary imaging in cancer patients

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 10, Issue 2, 2007, Pages

  Solbach, Christoph ^a,b   Patt, Marianne ^a,c   Reimold, M ^a   Blocher, A ^a,d   Dohmen, B M ^a   Bares, R ^a   Zeller, K P ^e   Machulla, Hans Juergen ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d SYNGENTA CROP PROTECTION AG   (Switzerland)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Carbon 11; Chemotherapy; Individual therapy planning; PET; Vinblastine

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 11; DIAZOMETHANE C 11; DIMETHYL SULFOXIDE; GUANOSINE PHOSPHATE; METHYL IODIDE C 11; POTASSIUM SALT; RADIOISOTOPE; SOLVENT; UNCLASSIFIED DRUG; VINBLASTINE; CARBON; DIAZOMETHANE; IODINATED HYDROCARBON; METHYL IODIDE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; AUTOMATION; CANCER PATIENT; CASE REPORT; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG RESPONSE; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; ISOTOPE LABELING; KIDNEY CARCINOMA; LIVER METABOLISM; METABOLITE; METASTASIS; METHYLATION; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; REACTION TIME; CHEMISTRY; KIDNEY TUMOR; METHODOLOGY; PHOTOSTIMULATION; SCINTISCANNING; SYNTHESIS; TEMPERATURE; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBON RADIOISOTOPES; CARCINOMA, RENAL CELL; CHEMISTRY, PHARMACEUTICAL; DIAZOMETHANE; HUMANS; HYDROCARBONS, IODINATED; ISOTOPE LABELING; KIDNEY NEOPLASMS; PHOTIC STIMULATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REACTION TIME; SOLVENTS; TEMPERATURE; TISSUE DISTRIBUTION; VINBLASTINE;

EID: 34447567065     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Dodd P.M., McCaffrey J.A., Mazumdar M., Scher H., Vlamis V., Higgins G., Herr H., Bajorin,m, D.F. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable of metastatic transitional cell carcinoma. Cancer 85: 1145-1150, 1999.
2. von der Maase H., Hansen S.W., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., Bodrogi I., Albers P., Knuth A., Lippert C.M., Kerbrat P., Sanchez Rovira P., Wersall P., Cleall S.P., Roychowdhury D.F., Tomlin I., Visseren-Grul C.M., Conte P.F. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol., 19: 1229-1231, 2001.
3. Dodd P.M., McCaffrey J.A., Herr H., Mazumdar M., Bacik J., Higgins G., Boyle M.G., Scher, H.I., Bajorin D.F. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J. Clin. Oncol., 17: 2546-2552, 1999.
4. Pyrhonen S., Salminen E., Ruutu M., Lehtonen T., Nurmi M., Tammela T., Juusela H., Rintala E., Hietanen P., Kellokumpu-Lehtinen P.L.. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol., 17: 2859-2867, 1999.
5. von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., Moore M.J., Zimmermann A., Arning M.. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine; doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol., 23: 4602-4608, 2005.
6. Lehmann J., Retz M., Wiemers C., Beck J., Thuroff J., Weining C., Albers P., Frohneberg D., Becker T., Funke P.J., Walz P., Langbein S., Reiher F., Schiller M., Miller K., Roth S., Kalble T., Sternberg D., Wellek S., Stockle M. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/ 95). J. Clin. Oncol., 23: 4963-4974, 2005.
7. Loehrer P.J. (Sr), Einhorn L.H., Elson P.J., Crawford E.D., Kuebler P., Tannock I., Raghavan D., Stuart-Harris R., Sarosdy M.F., Lowe B.A., Blumenstein B., Trump D. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol., 10: 1066-1073, 1992.
8. Roberts J.T. Chemotherapy for metastatic bladder cancer. Clin Oncol (R Coll Radiol),. 17: 514-523, 2005.
9. Garrett T.J., Vahdat L.T., Kinne D.W. Systemic adjuvant therapy of breast cancer. J. Surg. Oncol., 64: 167-172, 1997 (review).
10. Dolle F., Hinnen F., Valette H., Fuseau C., Duval R., Peglion J.L., Crouzel C. Synthesis of two optically active calcium channel antagonists labelled with carbon-11 for in vivo cardiac PET imaging. Bioorg. Med. Chem., 5: 749-764, 1997.
11. Stewart D.J., Lu K., Benjamin R.S., Leavens M.E., Luna M., Yap H.Y. Loo T.L. Concentration of vinblastine in human intracerebral tumor and other tissues. J. Neurooncol., 1: 139-144, 1983.
12. 11C]methane. Appl. Radiat. Isot., 48: 153-157, 1997.
13. 11C]diazomethane. Appl. Radiat. Isot.,: 2007 (accepted).
14. 11C]DASB: Application to a remotely controlled high yield synthesis. Radiochim. Acta 92: 341-344, 2004.
15. 11C]methyl triflate for β-amyloid imaging in Azheimer's Disease with PET. Appl. Radiat. Isot., 62: 591-595, 2005